Geron Corp. (GERN)

1.43
NASDAQ : Health Technology
Prev Close 1.44
Day Low/High 1.38 / 1.47
52 Wk Low/High 0.95 / 6.66
Avg Volume 1.58M
Exchange NASDAQ
Shares Outstanding 188.42M
Market Cap 271.33M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Geron (GERN) Trading With Heavy Volume Before Market Open

Geron (GERN) Trading With Heavy Volume Before Market Open

Trade-Ideas LLC identified Geron (GERN) as a pre-market mover with heavy volume candidate

This Biotech Stock Could Be the Next Big Short Squeeze

This Biotech Stock Could Be the Next Big Short Squeeze

The biotech sector is back in play on Wall Street in a big way, and anyone short the sector has to be feeling nervous

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

3 Biotech Stocks Under $10 to Watch

3 Biotech Stocks Under $10 to Watch

Keep an eye on these under-$10 biotech stocks.

Lieff Cabraser Reminds Geron Corporation Investors Of Upcoming Deadline In Class Action Litigation – GERN

Lieff Cabraser Reminds Geron Corporation Investors Of Upcoming Deadline In Class Action Litigation – GERN

Lieff, Cabraser, Heimann & Bernstein, LLP reminds investors of the May 13, 2014 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of those who purchased or acquired ...

2 Biotech Stocks Under $10 in Breakout Territory

2 Biotech Stocks Under $10 in Breakout Territory

Keep these under-$10 biotech stocks on your trading radar.

Hagens Berman Reminds Investors Of May 13, 2014, Lead Plaintiff Deadline In Geron Securities Class Action

Hagens Berman Reminds Investors Of May 13, 2014, Lead Plaintiff Deadline In Geron Securities Class Action

Hagens Berman Sobol Shapiro LLP a national investor-rights law firm, is investigating Geron Corporation (NASDAQ: GERN) (“Geron” or “the Company”) for securities fraud following allegations that the...

Lieff Cabraser Announces Class Action Litigation Against Geron Corporation - GERN

Lieff Cabraser Announces Class Action Litigation Against Geron Corporation - GERN

The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been brought on behalf of those who purchased or otherwise acquired the securities of Geron Corporation ...

Hagens Berman Advises Investors Of May 13, 2014, Deadline In Geron Corporation Securities Lawsuit And Investigation

Hagens Berman Advises Investors Of May 13, 2014, Deadline In Geron Corporation Securities Lawsuit And Investigation

Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is investigating Geron Corporation (NASDAQ: GERN) (“Geron” or “the Company”) for securities fraud following allegations that the...

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.

Geron Corporation (GERN) Showing Signs Of A Dead Cat Bounce Today

Geron Corporation (GERN) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified Geron Corporation (GERN) as a "dead cat bounce" (down big yesterday but up big today) candidate

Perilous Reversal Watch: Geron Corporation (GERN)

Perilous Reversal Watch: Geron Corporation (GERN)

Trade-Ideas LLC identified Geron Corporation (GERN) as a "perilous reversal" (up big yesterday but down big today) candidate

Goldman Scarlato Karon & Penny, P.C. Announces Investigation Of Geron Corporation

Goldman Scarlato Karon & Penny, P.C. Announces Investigation Of Geron Corporation

Goldman Scarlato Karon & Penny, P.C.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation Of GERON CORPORATION For Possible Breaches Of Fiduciary Duty

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation Of GERON CORPORATION For Possible Breaches Of Fiduciary Duty

Levi & Korsinsky commenced an investigation into Geron Corporation (“Geron” or the “Company”) (NasdaqGS:GERN) for possible breaches of fiduciary duty.

Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns

Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns

The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.

5 Stocks Ready to Explode Higher

5 Stocks Ready to Explode Higher

Here's a look at five stocks with potentially explosive chart patterns.

Trade-Ideas: Geron Corporation (GERN) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Geron Corporation (GERN) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Geron Corporation (GERN) as a "perilous reversal" (up big yesterday but down big today) candidate

Why Geron (GERN) Is Up Today

Why Geron (GERN) Is Up Today

Geron (GERN) was rising 12.24% to $4.86 on Thursday after the biotech company announced the pricing of its underwritten public offering of common stock.Geron, which announced the offering of 22.5 million shares earlier in the week, priced the stock at $4 per share. The company expects the gross proceeds from this offering to total approximately $90 million and expects the offering to close on or around Feb. 4, according to the company's statement.

Geron Corporation (GERN) Showing Signs Of A Dead Cat Bounce Today

Geron Corporation (GERN) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified Geron Corporation (GERN) as a "dead cat bounce" (down big yesterday but up big today) candidate

Geron Shares React to Imetelstat Mayo Study Update

Geron Shares React to Imetelstat Mayo Study Update

Geron shares are down about 15% in Monday's pre-market trading session in reaction to what appears to be a rather innocuous update on the Mayo Clinic's ongoing study of imetelstat in myelofibrosis patients.

Trade-Ideas: Geron Corporation (GERN) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas: Geron Corporation (GERN) Is Today's "Barbarian At The Gate" Stock

Trade-Ideas LLC identified Geron Corporation (GERN) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

J.P. Morgan Healthcare Confab Live Blog: Day Three

J.P. Morgan Healthcare Confab Live Blog: Day Three

TheStreet's Adam Feuerstein is providing live coverage of the most important healthcare investor conference of the year.

Geron Corporation (GERN) Highlighted As Today's Perilous Reversal Stock

Geron Corporation (GERN) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Geron Corporation (GERN) as a "perilous reversal" (up big yesterday but down big today) candidate

Geron Corporation (GERN) Is Today's Dead Cat Bounce Stock

Geron Corporation (GERN) Is Today's Dead Cat Bounce Stock

Trade-Ideas LLC identified Geron Corporation (GERN) as a "dead cat bounce" (down big yesterday but up big today) candidate

5 Under-$10 Biotech Stocks to Watch

5 Under-$10 Biotech Stocks to Watch

Keep these biotech stocks on your radar.

The Twitterverse's Biotech Stock Picks for 2014

The Twitterverse's Biotech Stock Picks for 2014

Biotech Twitter gets a chance to predict which stocks are worth buying this year.

Trade-Ideas: Geron Corporation (GERN) Is Today's "Perilous Reversal" Stock

Trade-Ideas: Geron Corporation (GERN) Is Today's "Perilous Reversal" Stock

Trade-Ideas LLC identified Geron Corporation (GERN) as a "perilous reversal" (up big yesterday but down big today) candidate

'Mad Money' Lightning Round: I Believe in Advanced Micro Devices

'Mad Money' Lightning Round: I Believe in Advanced Micro Devices

Cramer is riding with Hertz Global Holdings but is avoiding Tenet Healthcare.

Jim Cramer's 'Mad Money' Recap: A Down Day for the Market

Jim Cramer's 'Mad Money' Recap: A Down Day for the Market

Professional investors with cash on hand dream of days like today, but the price wasn't right for Cramer.

TheStreet Quant Rating: D (Sell)